| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 193 | 2024 | 2326 | 20.640 |
Why?
|
| Kidney Neoplasms | 187 | 2024 | 3022 | 18.210 |
Why?
|
| von Hippel-Lindau Disease | 22 | 2024 | 115 | 5.940 |
Why?
|
| Pyrroles | 21 | 2017 | 576 | 3.590 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 20 | 2023 | 155 | 3.550 |
Why?
|
| Indoles | 21 | 2017 | 1009 | 3.200 |
Why?
|
| Angiogenesis Inhibitors | 24 | 2022 | 1248 | 3.160 |
Why?
|
| Indazoles | 21 | 2021 | 297 | 2.650 |
Why?
|
| Antineoplastic Agents | 52 | 2021 | 14289 | 2.510 |
Why?
|
| Nephrectomy | 32 | 2023 | 779 | 2.130 |
Why?
|
| Everolimus | 13 | 2021 | 415 | 1.920 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 11 | 2023 | 622 | 1.850 |
Why?
|
| Vascular Endothelial Growth Factor A | 15 | 2022 | 1533 | 1.680 |
Why?
|
| Sulfonamides | 15 | 2021 | 1823 | 1.540 |
Why?
|
| Imidazoles | 11 | 2017 | 999 | 1.530 |
Why?
|
| Pyrimidines | 16 | 2021 | 3518 | 1.280 |
Why?
|
| Hemangioblastoma | 5 | 2024 | 22 | 1.260 |
Why?
|
| Humans | 250 | 2024 | 261506 | 1.240 |
Why?
|
| Protein Kinase Inhibitors | 24 | 2021 | 4757 | 1.220 |
Why?
|
| Pyridines | 10 | 2022 | 1244 | 1.090 |
Why?
|
| Anilides | 5 | 2022 | 268 | 1.040 |
Why?
|
| Neoplasm Metastasis | 27 | 2021 | 5112 | 1.010 |
Why?
|
| TOR Serine-Threonine Kinases | 8 | 2021 | 1546 | 1.010 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 2403 | 1.010 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2024 | 100 | 0.910 |
Why?
|
| Niacinamide | 10 | 2016 | 421 | 0.890 |
Why?
|
| Interferon-alpha | 8 | 2011 | 889 | 0.880 |
Why?
|
| Neuroendocrine Tumors | 6 | 2024 | 634 | 0.870 |
Why?
|
| Phenylurea Compounds | 12 | 2021 | 580 | 0.860 |
Why?
|
| Middle Aged | 109 | 2021 | 86204 | 0.850 |
Why?
|
| Sirolimus | 7 | 2016 | 814 | 0.840 |
Why?
|
| Bevacizumab | 11 | 2022 | 938 | 0.840 |
Why?
|
| Treatment Outcome | 62 | 2023 | 32848 | 0.810 |
Why?
|
| Biomarkers, Tumor | 25 | 2022 | 10331 | 0.800 |
Why?
|
| Male | 125 | 2022 | 123000 | 0.790 |
Why?
|
| Disease-Free Survival | 33 | 2018 | 10001 | 0.790 |
Why?
|
| Molecular Targeted Therapy | 15 | 2019 | 2330 | 0.770 |
Why?
|
| Brain Neoplasms | 7 | 2023 | 4849 | 0.770 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2021 | 8873 | 0.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2021 | 15862 | 0.750 |
Why?
|
| Female | 126 | 2022 | 141928 | 0.750 |
Why?
|
| Chemotherapy, Adjuvant | 17 | 2020 | 3890 | 0.730 |
Why?
|
| Proteasome Inhibitors | 2 | 2019 | 231 | 0.720 |
Why?
|
| Aged | 85 | 2021 | 70117 | 0.720 |
Why?
|
| Testicular Neoplasms | 5 | 2016 | 529 | 0.710 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2020 | 376 | 0.690 |
Why?
|
| Prognosis | 35 | 2023 | 21713 | 0.680 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 1439 | 0.630 |
Why?
|
| Adult | 82 | 2021 | 77950 | 0.620 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 43 | 0.620 |
Why?
|
| Aged, 80 and over | 48 | 2021 | 29902 | 0.610 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 33 | 0.610 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2022 | 221 | 0.600 |
Why?
|
| Pancreatic Neoplasms | 7 | 2024 | 5061 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 3251 | 0.590 |
Why?
|
| Oligopeptides | 1 | 2019 | 429 | 0.590 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2016 | 328 | 0.580 |
Why?
|
| Tumor Microenvironment | 6 | 2023 | 2864 | 0.580 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2021 | 1249 | 0.570 |
Why?
|
| Retrospective Studies | 52 | 2024 | 37905 | 0.570 |
Why?
|
| Survival Analysis | 23 | 2021 | 9180 | 0.560 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 146 | 0.550 |
Why?
|
| Mutant Proteins | 2 | 2014 | 234 | 0.550 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2020 | 661 | 0.530 |
Why?
|
| Benzenesulfonates | 5 | 2011 | 195 | 0.530 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2021 | 1756 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2018 | 419 | 0.520 |
Why?
|
| Uncertainty | 2 | 2013 | 320 | 0.500 |
Why?
|
| Quality of Life | 12 | 2021 | 4532 | 0.490 |
Why?
|
| Watchful Waiting | 2 | 2013 | 289 | 0.490 |
Why?
|
| Bone Neoplasms | 8 | 2017 | 2576 | 0.480 |
Why?
|
| Lysine | 2 | 2016 | 422 | 0.480 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 182 | 0.470 |
Why?
|
| Drug Administration Schedule | 8 | 2018 | 3472 | 0.460 |
Why?
|
| Medical Oncology | 6 | 2022 | 1423 | 0.450 |
Why?
|
| Radiosurgery | 5 | 2024 | 1330 | 0.440 |
Why?
|
| Histones | 4 | 2019 | 1466 | 0.440 |
Why?
|
| Transcription Factors | 7 | 2022 | 5270 | 0.440 |
Why?
|
| Immunotherapy | 9 | 2023 | 3341 | 0.430 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2019 | 461 | 0.430 |
Why?
|
| Proportional Hazards Models | 11 | 2016 | 4988 | 0.430 |
Why?
|
| Autophagy | 3 | 2016 | 927 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2018 | 2054 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 7 | 2019 | 4367 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2021 | 6207 | 0.420 |
Why?
|
| Survival Rate | 23 | 2021 | 12221 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2021 | 272 | 0.400 |
Why?
|
| Combined Modality Therapy | 13 | 2022 | 8865 | 0.400 |
Why?
|
| Disease Progression | 13 | 2021 | 6682 | 0.400 |
Why?
|
| Cancer Vaccines | 3 | 2008 | 697 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2019 | 5178 | 0.390 |
Why?
|
| Neoplasm Staging | 24 | 2020 | 13658 | 0.390 |
Why?
|
| Clinical Trials as Topic | 11 | 2021 | 3719 | 0.390 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 6 | 2021 | 355 | 0.390 |
Why?
|
| DNA-Binding Proteins | 5 | 2020 | 4821 | 0.380 |
Why?
|
| Neoplasms | 11 | 2023 | 15193 | 0.370 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 216 | 0.370 |
Why?
|
| Administration, Oral | 5 | 2021 | 1544 | 0.370 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 108 | 0.360 |
Why?
|
| Mutation | 21 | 2022 | 15179 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2021 | 4938 | 0.340 |
Why?
|
| Drug Discovery | 1 | 2012 | 324 | 0.340 |
Why?
|
| Risk Assessment | 14 | 2021 | 6869 | 0.330 |
Why?
|
| Cell Line, Tumor | 16 | 2023 | 14551 | 0.330 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2045 | 0.320 |
Why?
|
| Mice, Nude | 7 | 2021 | 4307 | 0.320 |
Why?
|
| Carcinoma, Medullary | 2 | 2023 | 248 | 0.320 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 5159 | 0.320 |
Why?
|
| United States | 12 | 2022 | 15433 | 0.320 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 423 | 0.320 |
Why?
|
| Animals | 27 | 2023 | 59536 | 0.320 |
Why?
|
| Lactoferrin | 1 | 2008 | 81 | 0.310 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 657 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 3 | 2022 | 1547 | 0.300 |
Why?
|
| Membrane Proteins | 2 | 2015 | 2819 | 0.300 |
Why?
|
| Young Adult | 24 | 2021 | 21445 | 0.290 |
Why?
|
| CRISPR-Cas Systems | 2 | 2021 | 323 | 0.290 |
Why?
|
| Prospective Studies | 14 | 2024 | 12873 | 0.290 |
Why?
|
| Follow-Up Studies | 18 | 2023 | 14889 | 0.290 |
Why?
|
| Nomograms | 1 | 2009 | 313 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 2359 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 2488 | 0.290 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 1005 | 0.290 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 311 | 0.280 |
Why?
|
| Glycosaminoglycans | 2 | 2023 | 61 | 0.280 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2017 | 315 | 0.270 |
Why?
|
| Writing | 3 | 2017 | 104 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 7 | 2014 | 4975 | 0.270 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 1382 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2021 | 10035 | 0.260 |
Why?
|
| DNA Methylation | 5 | 2021 | 2669 | 0.250 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 665 | 0.250 |
Why?
|
| Time Factors | 13 | 2018 | 12926 | 0.250 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 447 | 0.250 |
Why?
|
| Angiogenesis Inducing Agents | 3 | 2017 | 106 | 0.250 |
Why?
|
| Drug Delivery Systems | 5 | 2011 | 669 | 0.250 |
Why?
|
| Cell Dedifferentiation | 3 | 2020 | 96 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 2594 | 0.250 |
Why?
|
| Cytokines | 4 | 2017 | 2809 | 0.240 |
Why?
|
| Mice | 16 | 2023 | 34495 | 0.240 |
Why?
|
| Genomics | 7 | 2022 | 2738 | 0.240 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 1399 | 0.230 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 82 | 0.230 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 135 | 0.230 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 604 | 0.230 |
Why?
|
| Melanoma | 6 | 2005 | 5317 | 0.230 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 25 | 0.220 |
Why?
|
| Fluorouracil | 5 | 2010 | 1944 | 0.220 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 764 | 0.220 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2016 | 287 | 0.220 |
Why?
|
| Tumor Hypoxia | 2 | 2019 | 24 | 0.210 |
Why?
|
| Indenes | 1 | 2021 | 11 | 0.210 |
Why?
|
| Point Mutation | 2 | 2019 | 769 | 0.210 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3230 | 0.200 |
Why?
|
| Ear Canal | 1 | 2022 | 31 | 0.200 |
Why?
|
| Vaccination | 1 | 2008 | 1123 | 0.200 |
Why?
|
| Osteonecrosis | 1 | 2022 | 53 | 0.200 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2023 | 430 | 0.200 |
Why?
|
| Deoxycytidine | 5 | 2013 | 1353 | 0.200 |
Why?
|
| Capecitabine | 4 | 2010 | 388 | 0.200 |
Why?
|
| Central Nervous System | 1 | 2024 | 436 | 0.200 |
Why?
|
| Cranial Irradiation | 1 | 2023 | 315 | 0.200 |
Why?
|
| Phosphorylation | 7 | 2020 | 4804 | 0.200 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1516 | 0.190 |
Why?
|
| DNA Damage | 2 | 2023 | 1954 | 0.190 |
Why?
|
| Chromosomal Instability | 2 | 2023 | 233 | 0.190 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2019 | 154 | 0.190 |
Why?
|
| Disease Management | 4 | 2019 | 1052 | 0.190 |
Why?
|
| Pheochromocytoma | 3 | 2008 | 281 | 0.190 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 113 | 0.190 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2292 | 0.190 |
Why?
|
| Aneuploidy | 2 | 2023 | 369 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2013 | 489 | 0.190 |
Why?
|
| Methylation | 3 | 2019 | 597 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 90 | 0.190 |
Why?
|
| Antigen-Antibody Complex | 1 | 2020 | 115 | 0.190 |
Why?
|
| Endothelial Cells | 3 | 2022 | 1048 | 0.180 |
Why?
|
| Catheter Ablation | 3 | 2013 | 620 | 0.180 |
Why?
|
| Transcriptome | 5 | 2021 | 1859 | 0.180 |
Why?
|
| Cyclopentanes | 1 | 2020 | 40 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 986 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2021 | 167 | 0.180 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 589 | 0.180 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2001 | 115 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2020 | 1062 | 0.180 |
Why?
|
| Erythropoietin | 1 | 2021 | 205 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2019 | 7 | 0.180 |
Why?
|
| Aminohydrolases | 1 | 2019 | 7 | 0.180 |
Why?
|
| Sarcoma | 4 | 2020 | 1725 | 0.180 |
Why?
|
| Multifunctional Enzymes | 1 | 2019 | 12 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2021 | 551 | 0.180 |
Why?
|
| Histone Code | 2 | 2019 | 79 | 0.180 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 156 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2019 | 212 | 0.170 |
Why?
|
| Interferons | 1 | 2001 | 291 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 1022 | 0.170 |
Why?
|
| Immunohistochemistry | 5 | 2020 | 7548 | 0.170 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 254 | 0.170 |
Why?
|
| Depression | 6 | 2016 | 1715 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2016 | 7551 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 187 | 0.170 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 85 | 0.160 |
Why?
|
| Protein Isoforms | 3 | 2016 | 842 | 0.160 |
Why?
|
| Texas | 7 | 2021 | 6311 | 0.160 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 760 | 0.160 |
Why?
|
| Cell Cycle | 2 | 2017 | 2084 | 0.160 |
Why?
|
| Immune Tolerance | 2 | 2022 | 403 | 0.160 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 268 | 0.160 |
Why?
|
| Genomic Imprinting | 1 | 2019 | 194 | 0.160 |
Why?
|
| Methyltransferases | 1 | 2019 | 148 | 0.160 |
Why?
|
| Chromatin | 2 | 2013 | 942 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1350 | 0.160 |
Why?
|
| Signal Transduction | 9 | 2021 | 11965 | 0.160 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2018 | 518 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 2508 | 0.160 |
Why?
|
| Patient Selection | 3 | 2018 | 2055 | 0.150 |
Why?
|
| Cohort Studies | 9 | 2021 | 9244 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 657 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2022 | 674 | 0.150 |
Why?
|
| Cell Proliferation | 5 | 2017 | 7226 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 992 | 0.150 |
Why?
|
| Remission Induction | 5 | 2010 | 3569 | 0.150 |
Why?
|
| Ipilimumab | 2 | 2021 | 710 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1048 | 0.150 |
Why?
|
| Age of Onset | 2 | 2021 | 827 | 0.150 |
Why?
|
| Seminoma | 2 | 2015 | 81 | 0.150 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 101 | 0.150 |
Why?
|
| Prevalence | 4 | 2021 | 3260 | 0.150 |
Why?
|
| Embryonic Development | 1 | 2019 | 306 | 0.140 |
Why?
|
| Alleles | 2 | 2021 | 2437 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 1678 | 0.140 |
Why?
|
| Triazines | 1 | 2017 | 117 | 0.140 |
Why?
|
| Heterografts | 2 | 2017 | 733 | 0.140 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 149 | 0.140 |
Why?
|
| Expressed Emotion | 1 | 2016 | 22 | 0.140 |
Why?
|
| Glycolysis | 1 | 2019 | 519 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2014 | 1046 | 0.140 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2016 | 16 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2021 | 1234 | 0.140 |
Why?
|
| Protein Stability | 2 | 2020 | 370 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 598 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 561 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 275 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2020 | 5710 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 202 | 0.130 |
Why?
|
| Lipid Droplets | 1 | 2016 | 49 | 0.130 |
Why?
|
| Lymphoma, Follicular | 1 | 2001 | 587 | 0.130 |
Why?
|
| Incidence | 5 | 2015 | 5673 | 0.130 |
Why?
|
| Osteoblasts | 1 | 2017 | 370 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 2314 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 1265 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2015 | 122 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2023 | 2947 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 126 | 0.130 |
Why?
|
| DNA | 1 | 2023 | 2693 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 2016 | 267 | 0.130 |
Why?
|
| Interleukin-2 | 2 | 2009 | 842 | 0.130 |
Why?
|
| Oncogenes | 1 | 2018 | 673 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 451 | 0.130 |
Why?
|
| Community Networks | 1 | 2014 | 45 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2015 | 86 | 0.130 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 39 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 177 | 0.130 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 33 | 0.120 |
Why?
|
| Elongin | 1 | 2014 | 9 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2022 | 806 | 0.120 |
Why?
|
| Antineoplastic Protocols | 1 | 2014 | 33 | 0.120 |
Why?
|
| Beclin-1 | 1 | 2014 | 85 | 0.120 |
Why?
|
| Genetic Testing | 3 | 2021 | 1589 | 0.120 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.120 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 1258 | 0.120 |
Why?
|
| Pyrazines | 1 | 2017 | 495 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2015 | 392 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3821 | 0.120 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 50 | 0.120 |
Why?
|
| Skin Neoplasms | 4 | 2009 | 4654 | 0.120 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 741 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2017 | 351 | 0.120 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 11538 | 0.120 |
Why?
|
| Thalidomide | 2 | 2008 | 569 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2020 | 1171 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2016 | 200 | 0.120 |
Why?
|
| Biomarkers | 5 | 2023 | 5047 | 0.120 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 207 | 0.120 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 19 | 0.120 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2013 | 36 | 0.120 |
Why?
|
| Carbonic Anhydrases | 1 | 2013 | 44 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 1586 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2014 | 1391 | 0.120 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 54 | 0.110 |
Why?
|
| Apoptosis | 4 | 2017 | 7591 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 69 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2017 | 876 | 0.110 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 86 | 0.110 |
Why?
|
| Stress, Psychological | 3 | 2017 | 1000 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2015 | 5395 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 332 | 0.110 |
Why?
|
| HEK293 Cells | 2 | 2014 | 1489 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 534 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 3552 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 415 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 1143 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2015 | 262 | 0.110 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 2283 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 96 | 0.110 |
Why?
|
| Kidney | 3 | 2021 | 2146 | 0.110 |
Why?
|
| Liquid Biopsy | 2 | 2023 | 158 | 0.110 |
Why?
|
| Leupeptins | 1 | 2012 | 68 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 2927 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 840 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2012 | 94 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1130 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 582 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 1519 | 0.100 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 188 | 0.100 |
Why?
|
| Mass Screening | 2 | 2017 | 1509 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 691 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2018 | 1335 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2017 | 1682 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2016 | 1090 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 336 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 621 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 255 | 0.100 |
Why?
|
| Fatigue | 4 | 2021 | 1239 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2011 | 104 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2012 | 388 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 673 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6009 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2016 | 631 | 0.090 |
Why?
|
| Cadherins | 1 | 2014 | 660 | 0.090 |
Why?
|
| Risk Factors | 8 | 2019 | 17523 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 771 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1341 | 0.090 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 4298 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2021 | 2967 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 2216 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 584 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2021 | 2104 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 413 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2013 | 829 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 169 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2014 | 1152 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1033 | 0.090 |
Why?
|
| Emotions | 1 | 2014 | 562 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.090 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 4557 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 192 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1491 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 854 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1945 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 2527 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 554 | 0.080 |
Why?
|
| Hypertension | 2 | 2015 | 1503 | 0.080 |
Why?
|
| Keratosis, Actinic | 1 | 2009 | 37 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2017 | 5637 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2015 | 2450 | 0.080 |
Why?
|
| Salvage Therapy | 4 | 2018 | 2054 | 0.080 |
Why?
|
| Diphosphonates | 2 | 2011 | 262 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 1073 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2014 | 2074 | 0.080 |
Why?
|
| Adolescent | 11 | 2018 | 31252 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 607 | 0.080 |
Why?
|
| Nephrons | 1 | 2008 | 48 | 0.080 |
Why?
|
| Retreatment | 2 | 2021 | 452 | 0.080 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 195 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2014 | 1555 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5687 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 604 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 388 | 0.080 |
Why?
|
| Quinolines | 2 | 2021 | 383 | 0.080 |
Why?
|
| Genome, Human | 2 | 2013 | 1869 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 1450 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 1154 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 968 | 0.080 |
Why?
|
| Pneumonia | 1 | 2013 | 751 | 0.080 |
Why?
|
| Algorithms | 2 | 2009 | 3890 | 0.080 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 2 | 2019 | 43 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 434 | 0.070 |
Why?
|
| Cluster Analysis | 3 | 2017 | 1053 | 0.070 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 470 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2022 | 3981 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 962 | 0.070 |
Why?
|
| Consensus | 2 | 2021 | 978 | 0.070 |
Why?
|
| Glucose | 1 | 2013 | 1248 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2014 | 929 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1506 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2009 | 256 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2009 | 652 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 945 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2020 | 348 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2014 | 2022 | 0.070 |
Why?
|
| Forecasting | 1 | 2009 | 694 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 848 | 0.070 |
Why?
|
| Recurrence | 2 | 2017 | 4758 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 884 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 960 | 0.070 |
Why?
|
| Proteolysis | 2 | 2019 | 370 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2018 | 1987 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 5539 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2006 | 1144 | 0.060 |
Why?
|
| Ubiquitination | 2 | 2019 | 575 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3203 | 0.060 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1245 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2017 | 328 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 1823 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2018 | 549 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2017 | 276 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 66 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5319 | 0.060 |
Why?
|
| Patient Safety | 2 | 2021 | 649 | 0.060 |
Why?
|
| Risk | 1 | 2009 | 1972 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.060 |
Why?
|
| Quinazolines | 1 | 2009 | 923 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 4744 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 651 | 0.060 |
Why?
|
| Wound Healing | 1 | 2009 | 815 | 0.060 |
Why?
|
| Cell Line | 1 | 2012 | 5114 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2004 | 147 | 0.060 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 15694 | 0.060 |
Why?
|
| Child | 6 | 2020 | 29154 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 1077 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 155 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2021 | 1529 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 1656 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 511 | 0.060 |
Why?
|
| Chordoma | 1 | 2005 | 163 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2005 | 192 | 0.060 |
Why?
|
| Diarrhea | 2 | 2018 | 686 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2022 | 221 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2018 | 1764 | 0.050 |
Why?
|
| Endothelium | 1 | 2022 | 158 | 0.050 |
Why?
|
| Social Support | 2 | 2016 | 560 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2018 | 1869 | 0.050 |
Why?
|
| Tropomyosin | 1 | 2001 | 38 | 0.050 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2001 | 47 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 216 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 80 | 0.050 |
Why?
|
| Inflammation | 3 | 2022 | 2522 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 1489 | 0.050 |
Why?
|
| Lactones | 1 | 2001 | 94 | 0.050 |
Why?
|
| Receptors, Complement | 1 | 2021 | 48 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 3570 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 245 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 165 | 0.050 |
Why?
|
| Temporal Bone | 1 | 2022 | 102 | 0.050 |
Why?
|
| Postoperative Complications | 4 | 2011 | 5542 | 0.050 |
Why?
|
| Immunoassay | 2 | 2013 | 216 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 1 | 2001 | 259 | 0.050 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2000 | 42 | 0.050 |
Why?
|
| Antimanic Agents | 1 | 2000 | 39 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 22 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2021 | 221 | 0.050 |
Why?
|
| Amines | 1 | 2000 | 85 | 0.050 |
Why?
|
| Carboplatin | 1 | 2023 | 823 | 0.050 |
Why?
|
| Acetates | 1 | 2000 | 105 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 1271 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 90 | 0.040 |
Why?
|
| Phenotype | 4 | 2016 | 6295 | 0.040 |
Why?
|
| Microinjections | 1 | 2019 | 96 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2013 | 1643 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 309 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 419 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 371 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 74 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2005 | 1085 | 0.040 |
Why?
|
| Blastocyst | 1 | 2019 | 124 | 0.040 |
Why?
|
| Oogenesis | 1 | 2019 | 71 | 0.040 |
Why?
|
| Fear | 1 | 2020 | 254 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 475 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.040 |
Why?
|
| Hydroxylation | 1 | 2018 | 65 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2000 | 269 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 216 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 356 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 1382 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 16273 | 0.040 |
Why?
|
| Vidarabine | 1 | 2003 | 1341 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2019 | 311 | 0.040 |
Why?
|
| Retinal Neoplasms | 1 | 2019 | 144 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 400 | 0.040 |
Why?
|
| Osteolysis | 1 | 2017 | 80 | 0.040 |
Why?
|
| Age Factors | 1 | 2007 | 5377 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 141 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6100 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 189 | 0.040 |
Why?
|
| Exons | 2 | 2013 | 1328 | 0.040 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2019 | 291 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 627 | 0.040 |
Why?
|
| Double Bind Interaction | 1 | 2016 | 1 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 153 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 2000 | 376 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 310 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4078 | 0.040 |
Why?
|
| Oocytes | 1 | 2019 | 414 | 0.040 |
Why?
|
| Chymotrypsin | 1 | 2016 | 39 | 0.040 |
Why?
|
| Cytokinesis | 1 | 2016 | 57 | 0.040 |
Why?
|
| Fees, Pharmaceutical | 1 | 2016 | 3 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 521 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2020 | 1064 | 0.030 |
Why?
|
| Transfection | 1 | 2021 | 2944 | 0.030 |
Why?
|
| Tubulin | 1 | 2016 | 169 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 2315 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 175 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Anemia | 1 | 2021 | 689 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 85 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2005 | 1225 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2016 | 69 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2011 | 2316 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2018 | 501 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 43 | 0.030 |
Why?
|
| Palliative Care | 1 | 2007 | 2037 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 1581 | 0.030 |
Why?
|
| Microtubules | 1 | 2016 | 270 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 702 | 0.030 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 107 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 4844 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 866 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Macrophages | 1 | 2021 | 1304 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2014 | 52 | 0.030 |
Why?
|
| Dysphonia | 1 | 2014 | 11 | 0.030 |
Why?
|
| Neprilysin | 1 | 2014 | 66 | 0.030 |
Why?
|
| ras Proteins | 1 | 2019 | 770 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 556 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 445 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 2238 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| Sumoylation | 1 | 2014 | 84 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 619 | 0.030 |
Why?
|
| Mitosis | 1 | 2016 | 615 | 0.030 |
Why?
|
| Biopsy | 2 | 2013 | 3443 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 2013 | 49 | 0.030 |
Why?
|
| Proteinuria | 1 | 2014 | 155 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 476 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 2014 | 102 | 0.030 |
Why?
|
| Logistic Models | 2 | 2011 | 3441 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 102 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 130 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1363 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 227 | 0.030 |
Why?
|
| Models, Biological | 2 | 2015 | 3254 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 151 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 148 | 0.030 |
Why?
|
| Staurosporine | 1 | 2013 | 143 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 192 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 5437 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 354 | 0.030 |
Why?
|
| Affect | 1 | 2014 | 288 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2013 | 216 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 525 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 803 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 4143 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 134 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 269 | 0.030 |
Why?
|
| Ureteral Neoplasms | 1 | 2014 | 228 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 649 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2011 | 71 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 219 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 435 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2013 | 370 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 591 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 699 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2018 | 1549 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 886 | 0.020 |
Why?
|
| Protein Kinases | 2 | 2009 | 874 | 0.020 |
Why?
|
| Microvessels | 1 | 2012 | 135 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 96 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1070 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 671 | 0.020 |
Why?
|
| Caspases | 1 | 2013 | 661 | 0.020 |
Why?
|
| Camptothecin | 1 | 2013 | 517 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 2170 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 348 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 142 | 0.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 833 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 544 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2013 | 584 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2009 | 29 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 754 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Keratoacanthoma | 1 | 2009 | 18 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 1058 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 5767 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 6942 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2009 | 223 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2010 | 246 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 852 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 194 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2483 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2006 | 1303 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3536 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 2588 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 259 | 0.020 |
Why?
|
| Insulin | 1 | 2013 | 1454 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 188 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7702 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 984 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1910 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 621 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2006 | 130 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 4971 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2291 | 0.020 |
Why?
|
| Proteomics | 1 | 2013 | 1380 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7573 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2005 | 88 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3101 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2006 | 299 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2006 | 237 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 102 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 1879 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 108 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 752 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 1162 | 0.020 |
Why?
|
| Boston | 1 | 2005 | 108 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 159 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 3976 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 2005 | 145 | 0.020 |
Why?
|
| Cysts | 1 | 2006 | 197 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 1038 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7222 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 342 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3578 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2006 | 198 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2004 | 227 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 1890 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3154 | 0.020 |
Why?
|
| Adenoma | 1 | 2009 | 716 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 1960 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 810 | 0.010 |
Why?
|
| Cell Separation | 1 | 2005 | 612 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 672 | 0.010 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 139 | 0.010 |
Why?
|
| Pelvis | 1 | 2005 | 362 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 305 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6150 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 967 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 1863 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 1290 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 3343 | 0.010 |
Why?
|
| Stem Cells | 1 | 2009 | 1213 | 0.010 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2001 | 19 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2008 | 1529 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2001 | 116 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 4892 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 4917 | 0.010 |
Why?
|
| Macrolides | 1 | 2001 | 62 | 0.010 |
Why?
|
| Cell Size | 1 | 2001 | 136 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2001 | 355 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 2341 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 394 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4549 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 6089 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 160 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2001 | 246 | 0.010 |
Why?
|
| Melphalan | 1 | 2003 | 834 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 1479 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2000 | 163 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 3033 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 639 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 1008 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 2489 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 2843 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 2638 | 0.010 |
Why?
|